KYVERNA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13 USD | +4.59% |
|
-15.69% | 0.00% |
| May. 14 | Kyverna Therapeutics Q1 Loss Narrows | MT |
| Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 560.5 | - | - |
| Enterprise Value (EV) 1 | 364.8 | 422.2 | 362.4 |
| P/E ratio | -3.61 x | -3.07 x | -2.77 x |
| Yield | - | - | - |
| Capitalization / Revenue | 149 x | 112 x | 67.3 x |
| EV / Revenue | 97.3 x | 84.4 x | 43.5 x |
| EV / EBITDA | -2.51 x | -2.14 x | -1.7 x |
| EV / FCF | -2.89 x | -2.27 x | - |
| FCF Yield | -34.5% | -44.1% | - |
| Price to Book | 5.16 x | -7.18 x | 100 x |
| Nbr of stocks (in thousands) | 43,115 | - | - |
| Reference price 2 | 13.00 | 13.00 | 13.00 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 3.75 | 5 | 8.333 |
| EBITDA 1 | - | -60.7 | -145.3 | -197 | -213.1 |
| EBIT 1 | - | -62.41 | -142.4 | -199.3 | -211.7 |
| Operating Margin | - | - | -3,796.91% | -3,985.39% | -2,540.87% |
| Earnings before Tax (EBT) 1 | - | -60.37 | -139.8 | -193.8 | -218.5 |
| Net income 1 | -28.89 | -60.37 | -138.1 | -196.8 | -230.8 |
| Net margin | - | - | -3,683.8% | -3,935.66% | -2,770.07% |
| EPS 2 | -13.94 | -89.61 | -3.602 | -4.237 | -4.685 |
| Free Cash Flow 1 | - | -53.03 | -126 | -186 | - |
| FCF margin | - | - | -3,360% | -3,720% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 10/5/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | -20.92 | - | -36 | -44 | -51 |
| EBIT 1 | -21.38 | -29.36 | -34 | -39.5 | -44.5 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | - | -34 | -41 | -49 |
| Net income 1 | - | - | -31.8 | -38.45 | -45.75 |
| Net margin | - | - | - | - | - |
| EPS 2 | -75.82 | -1.120 | -0.7531 | -0.8627 | -0.9934 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/26/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 196 | 138 | 198 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -53 | -126 | -186 | - |
| ROE (net income / shareholders' equity) | - | - | -99.3% | -648% | - |
| ROA (Net income/ Total Assets) | - | - | -79% | -55.9% | - |
| Assets 1 | - | - | 174.8 | 352 | - |
| Book Value Per Share 2 | - | - | 2.520 | -1.810 | 0.1300 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.62 | 1.5 | 5 | - |
| Capex / Sales | - | - | 40% | 100% | - |
| Announcement Date | 10/5/23 | 3/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13
USD
Average target price
42.75
USD
Spread / Average Target
+228.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 560M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.04% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- KYTX Stock
- Financials Kyverna Therapeutics, Inc.
